# US 2003/0073694 A1 · Antibiotic compositions and methods for using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073694 A1
- Document ID: US20030073694A1
- Status: Published application
- Kind: A1
- Application number: 10/194,834
- Filed: 2002-07-12
- Published: 2003-04-17
- Earliest claimed: 1999-07-30
- Assignees: Allergan Sales, Inc.
- Inventors: Christopher A. Muller; Elizabeth A. Bancroft; Janet K. Cheetham; Harold G. Jensen; Teresa H. Kuan; David F. Power; Kevin D. Skule
- Web page: https://patentgrep.com/patent/US20030073694A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.

## Claims

### Claim 1

A composition comprising:
a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye;
a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye; and
a carrier component in an amount effective to act as a carrier for the quinolone component and the NSAID component in the composition, the carrier component being ophthalmically acceptable, the composition being substantially free of other components effective as preservatives.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the NSAID component is a carboxyl group-containing NSAID component.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the carrier component is selected to provide the composition in a form selected from the group consisting of a solution, a suspension, a gel, an ointment and a solid.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the quinolone component is a halogenated quinolone component.

### Claim 5 (depends on 4)

The composition of claim 4 wherein the NSAID component is a carboxyl group-containing NSAID component.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the quinolone component is a fluorinated quinolone component.

### Claim 7 (depends on 6)

The composition of claim 6 wherein the NSAID component is a carboxyl group-containing NSAID component.

### Claim 8 (depends on 1)

The composition of claim 1 wherein the quinolone component is an ofloxacin component

### Claim 9 (depends on 8)

The composition of claim 8 wherein the NSAID component is a carboxyl group-containing NSAID component.

### Claim 10 (depends on 1)

The composition of claim 1 wherein the NSAID component is a ketorolac component.

### Claim 11 (depends on 10)

The composition of claim 10 wherein the carrier component is selected to provide the composition in a form selected from the group consisting of a solution, a suspension, a gel and an ointment.

### Claim 12 (depends on 10)

The composition of claim 10 wherein the quinolone component is a halogenated quinolone component.

### Claim 13 (depends on 10)

The composition of claim 10 wherein the quinolone component is a fluorinated quinolone component.

### Claim 14 (depends on 10)

The composition of claim 10 wherein the quinolone component is an ofloxacin component

### Claim 15 (depends on 1)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 1, thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.

### Claim 16 (depends on 3)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 3, thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.

### Claim 17 (depends on 4)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 4, thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.

### Claim 18 (depends on 8)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 8, thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.

### Claim 19 (depends on 10)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 10, thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.

### Claim 20 (depends on 14)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 14, thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.

### Claim 21

A composition comprising:
a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, the quinolone component in the composition having fungistatic activity; and
a carrier component in an amount effective to act as a carrier for the quinolone component in the composition, the component being ophthalmically acceptable, the composition being substantially free of other components effective as preservatives.

### Claim 22 (depends on 21)

The composition of claim 21 wherein the carrier component is selected to provide the composition in a form selected from the group consisting of a solution, a suspension, a gel, an ointment and a solid.

### Claim 23 (depends on 21)

The composition of claim 21 wherein the quinolone component is a halogenated quinolone component.

### Claim 24 (depends on 21)

The composition of claim 21 wherein the quinolone component is a fluorinated quinolone component.

### Claim 25 (depends on 21)

The composition of claim 21 wherein the quinolone component is an ofloxacin component

### Claim 26 (depends on 21)

The composition of claim 21 which further comprises an additional active component in an amount effective to provide a therapeutic effect when the composition is placed in a mammalian eye, the carrier component being effective to act as a carrier for the additional active component.

### Claim 27 (depends on 26)

The composition of claim 26 wherein the additional active component is a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye.

### Claim 28 (depends on 27)

The composition of claim 27 wherein the NSAID component is a carboxyl group containing NSAID component.

### Claim 29 (depends on 27)

The composition of claim 27 wherein the NSAID component is a ketorolac component.

### Claim 30 (depends on 29)

The composition of claim 29 wherein the quinolone component is an ofloxacin component.

### Claim 31 (depends on 21)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 21.

### Claim 32 (depends on 22)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 22.

### Claim 33 (depends on 25)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 25.

### Claim 34 (depends on 29)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 29.

### Claim 35 (depends on 30)

A method for treating a mammalian eye comprising:
administering to the mammalian eye a therapeutically effective amount of the composition of claim 30.
